Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia
- 10 December 2015
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 99 (6), 651-660
- https://doi.org/10.1002/cpt.315
Abstract
Using broad interrogation of clinically relevant drug absorption, distribution, metabolism, and excretion (ADME) genes on the DMET platform, we identified a genetic variant in SLCO1B1 (rs2291075; c.597C>T), encoding the transporter OATP1B1, associated with event‐free (P = 0.006, hazard ratio = 1.74) and overall survival (P = 0.012, hazard ratio = 1.85) in children with de novo acute myeloid leukemia (AML). Lack of SLCO1B1 expression in leukemic blasts suggested the association might be due to an inherited rather than a somatic effect. rs2291075 was in strong linkage with known functional variants rs2306283 (c.388A>G) and rs4149056 (c.521T>C). Functional studies in vitro determined that four AML‐directed chemotherapeutics (cytarabine, daunorubicin, etoposide, and mitoxantrone) are substrates for OATP1B1 and the mouse ortholog Oatp1b2. In vivo pharmacokinetic studies using Oatp1b2‐deficient mice further confirmed our results. Collectively, these findings demonstrate an important role for OATP1B1 in the systemic pharmacokinetics of multiple drugs used in the treatment of AML and suggest that inherited variability in host transporter function influences the effectiveness of therapy.Keywords
Funding Information
- National Institutes of Health Cancer Center (P30 CA021765)
- American Lebanese Syrian Associated Charities (ALSAC)
This publication has 49 references indexed in Scilit:
- Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate dispositionGenome Research, 2011
- Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple‐transfected MDCK‐OATP1B1‐UGT1A1‐MRP2 cellsBritish Journal of Pharmacology, 2011
- Genetic Variants in Cytosolic 5′-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid LeukemiaThe Journal of pharmacology and experimental therapeutics, 2011
- Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin ConcentrationsAntimicrobial Agents and Chemotherapy, 2010
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialThe Lancet Oncology, 2010
- SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMapBioinformatics, 2008
- Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and RifampinMolecular Pharmacology, 2008
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- The International HapMap ProjectNature, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999